Prestwick Pharmaceuticals, Inc. Release: Study Published In Neurology Shows Tetrabenazine Significantly Improves Debilitating Movement Disorder Caused By Huntington's Disease
New data show the investigational therapy tetrabenazine, at dosages adjusted to patient response and side effects, titrated up to 100 mg per day, significantly improved clinical outcomes and reduced symptoms of chorea associated with Huntington's Disease (HD), a debilitating neurological disorder marked by incessant involuntary movements for which there is no approved therapy in the United States.